Safe Handling Guidelines Needed for Gene Therapies in the Clinic

News
Article

Current handling guidelines do not align between the laboratory and clinical settings.

Kevin Zinchuk, PharmD, CCRP, Pharmacy Manager, Investigational Drug Services, Brigham and Women’s Hospital.

Kevin Zinchuk, PharmD, CCRP

Credit: Brighman and Women's Hospital

The growing prevalence of gene therapies being used in the clinic necessitates developing standardized guidelines for safe handling of gene therapy products in a healthcare setting.

A poster detailing the need for such guidelines was presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, held May 7 to 10, 2024, in Baltimore, Maryland, by Kevin Zinchuk, PharmD, CCRP, Pharmacy Manager, Investigational Drug Services, Brigham and Women’s Hospital.

“The current guidance for grading the risk of viral vectors in the laboratory setting, the NIH risk categories and CDC biosafety levels, doesn't translate to the risk categorizations that we use in the clinical setting, which is the NIOSH list of hazardous drugs and USP 800," Zinchuk told CGTLive® during the ASGCT meeting. “As more and more gene therapies move from the lab setting into human clinical trials and are being used in large academic medical centers around the country and around the world, we need to better define our processes for safe handling practices in the institutional setting.”

The researchers outlined current guidelines used in different settings. Currently used to guide handling in laboratory settings are the National Institutes of Health (NIH) risk categories and the Center for Disease Control (CDC) Biological Safety Level, both of which grade agents according to pathogenicity, transmission, and treatability of the agent.

READ MORE: Ethical Framework Needed for Gene Therapy Clinical Trials

On the other hand, currently in clinical settings, the NIOSH list of Hazardous Drugs and USP <800> set the standard for handling drugs. These criteria characterize drugs according to carcinogenicity, teratogenicity/developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or new drugs that mimic existing hazardous drugs in structure or toxicity.

“With an increasing volume of viral vector-based gene therapies on the horizon, ensuring the safety and protection of healthcare workers handling these agents is of the utmost importance. Staff who prepare and administer these agents, as well as those caring for patients, must be considered, as occupational health, quality and safety administrators develop safe handling policies and procedures at their institutions,” Zinchuk and colleagues wrote.

As existing guidelines in the lab and clinical settings do not align, there is a need to develop standard operating procedures for the clinical setting that draw from existing guidelines. New guidelines must consider the roles and responsibilities of personnel; staff training; personal protection equipment; types of exposure; receipt, storage, and preparation of gene therapy agents; labeling packaging, transportation, and waste disposal; administration; spill control, and other factors.

“Institutions must build a team led by pharmacy to address the creation of policies and procedures to manage the safe handling of gene therapies in clinical settings. In addition to pharmacy, this team should include representatives from the institutional biosafety committee, infection control, facilities, nursing, and medicine,” Zinchuck and colleagues wrote in their poster. “Pharmacists must become institutional leaders in the oversight of gene therapy use as they are an integral component in every stepof the medication use process for these novel therapeutics. Mechanisms for this newly established team to address include policy and procedure creation, staff education, and regulatory compliance. “

REFERENCE
Rodriguez E, Zinchuk K, Stackhouse JR, et al. Recommendations for the safe handling of gene therapy in institutional settings. Presented at: ASGCT 27th Annual Meeting, May 7-10; Baltimore, Maryland. Abstract #924
Recent Videos
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
© 2024 MJH Life Sciences

All rights reserved.